Key facts
- This page summarizes Todd E. Simpson's Form 4 filing for Seagen Inc..
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Aug 2023, 20:47.
Todd E. Simpson - 15 Aug 2023 Form 4 Insider Report for Seagen Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 15 Aug 2023
- Net transaction value
- -$679,898
- SEC form
- 4
- Accepted by SEC
- 17 Aug 2023, 20:47:08 UTC
- Prior SEC filing
- 09 Jun 2023
- Next SEC filing
- 30 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jessica Nielsen Causey For: Todd E Simpson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Todd E. Simpson filed Form 4 for Seagen Inc. on 17 Aug 2023.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: -$679,898.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGEN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +14,746
- Change %
- +12%
- Price
- $0.000000
- Shares after
- 133,692
- Date
- 15 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
SGEN
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $214,419
- Shares
- -1,106
- Change %
- -0.83%
- Price
- $193.87
- Shares after
- 132,586
- Date
- 16 Aug 2023
- Ownership
- Direct
- Footnotes
- F3, F4
SGEN
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $166,921
- Shares
- -861
- Change %
- -0.65%
- Price
- $193.87
- Shares after
- 131,725
- Date
- 16 Aug 2023
- Ownership
- Direct
- Footnotes
- F3, F5
SGEN
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $298,558
- Shares
- -1,540
- Change %
- -1.2%
- Price
- $193.87
- Shares after
- 130,185
- Date
- 16 Aug 2023
- Ownership
- Direct
- Footnotes
- F3, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 6 footnotes
Footnote F1
These shares represent restricted stock units and will be settled in common stock upon vesting. 40% of the reporting person's annual equity award was granted in the form of performance stock units, which are not reflected here, and will be treated the same as these restricted stock units in the event the transaction with Pfizer closes.
Footnote F2
Shares shall vest at a rate of 25% on each anniversary of August 15, 2023 until all shares are fully vested at the end of four years.
Footnote F3
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Footnote F4
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/3/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Footnote F5
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/5/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Footnote F6
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 10/15/2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).